Business Details
Your Trusted Partner for Biopharmaceutical Innovation
At Biohaven Pharmaceutical Holding, we operate with urgency and intention to transform groundbreaking science into life-changing therapies for patients with unmet medical needs. Our legacy of delivering first-in-class treatments like Nurtec ODT and Zavzpret demonstrates our expertise in clinical execution and proprietary drug development platforms. With a decentralized leadership structure and a team of seasoned professionals, we advance a robust pipeline spanning neuroscience, immunology, and oncology, driven by our commitment to follow science without limitations.Our collaborations with leading institutions and focus on digital innovation enable us to accelerate therapies while maintaining rigorous standards of safety and efficacy. By prioritizing patient needs and fostering a culture of accountability, we aim to disrupt traditional approaches to drug discovery and create lasting value for stakeholders.
Services
Neuroscience Therapies
Immunology Treatments
Oncology Solutions
Clinical Trials
Drug Development Platforms
Patient-Centric Research
Global Collaborations
Innovation Pipeline
Early Access Programs
Scientific Advisory
Highlights and features
- We deliver first-in-class treatments validated by FDA approvals and clinical success.
- Our proprietary platforms enable rapid development of novel therapies for complex diseases.
- Decentralized leadership ensures agile decision-making and faster innovation cycles.
- Collaborations with top institutions enhance our research and development capabilities.
- Patient-first culture drives every stage of our drug discovery and delivery process.
Services
Neuroscience Therapies
Biohaven Pharmaceutical Holding develops targeted therapies for neurological disorders like epilepsy, Parkinson's disease, and spinal muscular atrophy. Our programs leverage advanced platforms such as Kv7 ion channel modulation and TYK2/JAK1 inhibition to address disease mechanisms at the molecular level. These treatments aim to improve patient outcomes through enhanced efficacy, reduced side effects, and novel approaches to neuroinflammation and neurodegeneration.
Immunology Treatments
Our immunology pipeline focuses on modulating immune responses for conditions like rheumatoid arthritis and myasthenia gravis. Using proprietary MoDE technology, we target pathogenic antibodies and inflammatory pathways with precision. These therapies aim to provide safer, more effective alternatives to existing treatments by addressing root causes of autoimmune dysfunction.
Oncology Solutions
Biohaven Pharmaceutical Holding's oncology programs utilize antibody-drug conjugates (ADCs) and bispecific molecules to target cancers like Hodgkin lymphoma and urothelial cancer. These approaches combine targeted delivery with potent cytotoxic agents to maximize therapeutic impact while minimizing systemic toxicity. Our research explores novel mechanisms to improve survival rates and quality of life for cancer patients.
Clinical Trials
We conduct Phase 1-3 clinical trials for investigational therapies across multiple disease areas. Our trials emphasize rigorous methodology, patient safety, and accelerated timelines to bring promising treatments to market. By integrating digital tools and biomarker analysis, we enhance trial efficiency and data-driven decision-making.
Drug Development Platforms
Our platforms include TRPM3 antagonism, myostatin inhibition, and extracellular protein degradation technologies. These modular systems enable rapid generation of novel therapies tailored to specific disease pathways. By optimizing drug candidates for bioavailability and target engagement, we increase the likelihood of clinical success.
People
Vlad Coric
Chairman & CEO
Dr. Coric leads Biohaven Pharmaceutical Holding's strategic vision, leveraging over 20 years of experience in neuroscience drug development. He has spearheaded the company's growth from a startup to a leader in innovative therapeutics.
Questions
What therapeutic areas does Biohaven Pharmaceutical Holding focus on?
Biohaven Pharmaceutical Holding prioritizes neuroscience, immunology, and oncology, targeting diseases with significant unmet medical needs through innovative research and development.
How does Biohaven Pharmaceutical Holding accelerate drug development?
We use proprietary platforms, decentralized leadership, and digital tools to streamline clinical trials and optimize R&D efficiency while maintaining rigorous safety standards.
What is Biohaven Pharmaceutical Holding's approach to patient care?
Our patient-first culture ensures therapies are developed with urgency, transparency, and a focus on improving quality of life for individuals with debilitating conditions.
Does Biohaven Pharmaceutical Holding collaborate with other organizations?
Yes, we partner with leading institutions like Yale University and Pfizer to enhance our research capabilities and expand our therapeutic pipeline.
How can I learn about clinical trials?
Visit BiohavenClinicalTrials.com for details on ongoing studies, eligibility criteria, and how to participate in advancing medical research.
